原发性肝癌患者血清白细胞介素6的测定及临床意义

目的　探讨血清白细胞介素 6与原发性肝癌发生、发展、转移、疗效及预后的关系。方法　采用ELISA法 (双抗体夹心酶联免疫吸附试验 )检测了 6 8例原发性肝癌患者和 15例良性肝肿瘤患者治疗前后及 32例肝硬化患者的血清IL 6含量 ,再进行比较分析。结果　原发性肝癌患者血清IL 6水平明显高于正常人、肝硬化及良性肝肿瘤患者 (P <0 .0 1) ,且与肿瘤直径、有无腹腔积液、有无肝外转移、临床分期及治疗效果有关 ,与血清AFP呈正相关。结论　原发性肝癌患者血清IL 6水平在一定程度上可反映肝癌发生、发展、转移情况及治疗效果 ,可能成为预测肝癌转移、复发及疗效的有效指标 ,与AFP同时检测 ,有望提高原发性肝癌的早期诊断。

Clinical significance of serum interleakin-6 in patients with primary liver cancer

Objective To study the relationships between serum interleakin 6 and the development,metastasis,curative effect and prognosis of primary liver cancer. Methods The serum interleakin 6 in 68 patients with primary liver cancer,15 patients with various benign liver tumor and 32 patients with cirrhosis of liver were determined by ELISA method before and after treatment. Results The serum interleakin 6 level of patients with primary liver cancer was significantly higher than that in control groups and the patients with various benign liver tumour or cirrhosis of liver( P <0.01),and correlated with tumor diameter,ascites,metastasis,clinical stages and curative effect. And the interleakin 6 level have positive relation to AFP level. Conclusion The serum interleakin 6 levels could be a marker of occurrence, stage and metastasis of the primary liver cancer and may play a role in biological character of hepatoma cell and curative effect. And our present data suggest that combining examinations of interleakin 6 and AFP can increase the positive rate of diagnosis.